Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera BGI Genomics License Agreement by Quarter
BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025] ($M)
Natera BGI Genomics License Agreement: $16.4M in Q3 2025, down 3.0% from a year earlier.
Latest, Q3 2025
16.4
Period ended Sep 30, 2025
Change on a year earlier
-3.0%
16.9 in Q3 2024
History
15 quarters
Since Q2 2019
Sources
15
Documents cited below
Where the Q3 2025 figure comes from
Source: Form 10-Q (2025-11-07) ↗
Reported in Form 10-K/10-Q Note — Collaborative & Licensing Arrangements (2019–2025Q3).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2025 | Sep 30, 2025 | 16.4 | -3.0% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 16.5 | -10.3% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 16.7 | -3.5% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 16.8 | -4.5% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 16.9 | -12.4% | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 18.4 | -7.1% | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 17.3 | -12.6% | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 17.6 | -12.0% | Form 10-K (2024-02-29) ↗ |
| Q3 2023 | Sep 30, 2023 | 19.3 | – | Form 10-Q (2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 19.8 | – | Form 10-Q (2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 19.8 | – | Form 10-Q (2023-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 20 | -2.0% | Form 10-K (2023-03-01) ↗ |
| Q4 2021 | Dec 31, 2021 | 20.4 | – | Form 10-K (2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 16.1 | – | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 20.0 | – | Form 10-Q (2019-08-09) ↗ |
Cite this data
StockData. (2026). Natera BGI Genomics License Agreement ($M), quarterly Q2 2019–Q3 2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-bgi-noncurrent
See every metric in the Natera KPI table. Data updated Nov 2, 2026.